Biosyngen
Singapore
About Biosyngen
Biosyngen is developing multiple T-cell immunotherapies with the aim to address a wide range of malignancies. BioSyngen Group is dedicated in the clinical and commercial transfer of innovative immune-cell therapy technologies and products. It develops immune cell therapies for aggaressive cancers.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Total funding: $78.2M
- Last round: Series Unknown (Oct 2021)
- Website: biosyngen.com
- Phone: +65 6914 9306
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/biosyngen-11074 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.